INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $800,311 | -15.7% | 15,364 | +2.5% | 0.00% | -25.0% |
| Q2 2023 | $949,357 | +28.7% | 14,993 | +10.0% | 0.00% | +33.3% |
| Q1 2023 | $737,794 | -6.1% | 13,625 | -8.2% | 0.00% | -25.0% |
| Q4 2022 | $785,439 | +109.5% | 14,842 | +84.3% | 0.00% | +100.0% |
| Q3 2022 | $375,000 | +29.3% | 8,054 | -11.8% | 0.00% | +100.0% |
| Q4 2020 | $290,000 | -50.1% | 9,132 | -82.1% | 0.00% | -75.0% |
| Q4 2018 | $581,000 | -62.8% | 51,030 | -29.0% | 0.00% | -50.0% |
| Q3 2018 | $1,560,000 | -11.2% | 71,905 | -27.6% | 0.01% | -20.0% |
| Q2 2018 | $1,756,000 | +132.9% | 99,370 | +63.7% | 0.01% | +100.0% |
| Q2 2017 | $754,000 | – | 60,720 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |